ASRT: Assertio Holdings, Inc. Stock

by  •  • Comments Off on ASRT: Assertio Holdings, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 79.31
Enterprise Value ($M) 80.17
Book Value ($M) 130.52
Book Value / Share 1.37
Price / Book 0.61
NCAV ($M) 35.67
NCAV / Share 0.37
Price / NCAV 2.22

Profitability (mra)
Return on Invested Capital (ROIC) -0.40
Return on Assets (ROA) -0.24
Return on Equity (ROE) -0.50

Liquidity (mrq)
Quick Ratio 1.57
Current Ratio 2.01

Balance Sheet (mrq) ($M)
Current Assets 181.16
Assets 276.00
Liabilities 145.48
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Armistice Capital, Llc 0.00 -100.00
11-12 13G/A Vanguard Group Inc 4.68 0.00
07-08 13G/A BlackRock, Inc. 1.50 -78.92
02-14 13G/A Continental General Insurance Co 0.00 -100.00
02-14 13G Nantahala Capital Management, LLC 8.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-05-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-11 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-10 118,831 498,253 23.85
2025-01-08 203,768 631,029 32.29
2025-01-07 143,055 459,414 31.14

(click for more detail)

Similar Companies
APVO – Aptevo Therapeutics Inc. ARTL – Artelo Biosciences, Inc.
ASNS – Actelis Networks, Inc. ATNF – 180 Life Sciences Corp.
ATOS – Atossa Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io